Skip to content
naulon

Not checkedNot checked for notices yet.

<it>HER2 </it>Amplification Has no Prognostic Value in Sporadic and Hereditary Ovarian Tumours

Brożek Izabela, Kardaś Iwona, Ochman Karolina and 6 more

Hereditary Cancer in Clinical Practice · 2006

doi:10.1186/1897-4287-4-1-39 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Whereas <it>HER2 </it>amplification is a well-known phenomenon in breast tumours, its frequency and clinical importance in ovarian cancer have not been established. The aim of the study was to compare the frequency of <it>HER2 </it>amplification in hereditary (<it>BRCA</it>-positive) and sporadic (<it>BRCA</it>-negative) ovarian tumours and to estimate the association of this gene alteration on clinical outcome in ovarian cancer patients. We analysed <it>HER2 </it>amplification in 53 ovarian tumours: 20 from mutation carriers (18 in <it>BRCA1 </it>and 2 in <it>BRCA2 </it>gene) and 33 from non-carriers. Fluorescence <it>in situ </it>hybridization for <it>HER2 </it>was performed on 'touch' slides from frozen tumour samples or formalin-fixed, paraffin-embedded tissue. Our results indicate that high amplification (<it>HER2</it>: centromere ratio>5) is an infrequent phenomenon in ovarian tumours (6/53 cases). It occurs in both hereditary (4/20) and sporadic (2/33) tumours and no difference in the frequency of <it>HER2 </it>amplification exists between these groups. There is no significant difference in the clinical outcome of patients with <it>HER2 </it>amplified and non-amplified tumours (p = 0.3). Our results suggest a different biological role of <it>HER2 </it>amplification in ovarian and breast cancer.</p>

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.